- Home
- TRXB vs CCCC Comparison
TRXB vs CCCC Comparison
Compare TRXB & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TRXB | CCCC |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 388.6M | 350.6M |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | TRXB | CCCC |
|---|---|---|
| Price | $14.88 | $2.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $12.86 |
| AVG Volume (30 Days) | N/A | ★ 2.3M |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.45 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | N/A | $1.69 |
| 52 Week High | N/A | $5.17 |
Technical Indicators
Market Signals| Indicator | TRXB | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 44.27 |
| Support Level | N/A | $2.88 |
| Resistance Level | N/A | $3.25 |
| Average True Range (ATR) | 0.00 | 0.21 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 0.00 | 41.67 |
Price Performance
Historical ComparisonAbout CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.